SON-1010

Sonnet BioTherapeutics · Phase 1 active Biologic

At a glance

Generic name	SON-1010
Also known as	IL12-FHAB
Sponsor	Sonnet BioTherapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (PHASE1)
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer (PHASE1, PHASE2)
Study of SON-1010 (IL12-FHAB) in Healthy Adults (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SON-1010 CI brief — competitive landscape report
SON-1010 updates RSS · CI watch RSS
Sonnet BioTherapeutics portfolio CI